The role of autophagy in initiation, progression, TME modification, diagnosis, and treatment of esophageal cancers

Zhou, Suna; Sun, Xuefeng; Jin, Zhicheng; Yang, Haihua; Ye, Wenguang

doi:10.1016/j.critrevonc.2022.103702

Cited by 8 publications

(6 citation statements)

References 138 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In ammation has been demonstrated to be closely related to all stages of development and malignant progression of TNBC [33] . Once in ammatory tumor microenvironment (TME) is established, in ammatory factors from tumor cells or interstitial cells would induce breast cancer cells proliferation by initially activating oncogenes and subsequently inactivating tumor suppressor genes [34][35] . It follows that controlling in ammation appears to be an important approach to a more effective anticancer treatment [36] .…”

Section: Discussionmentioning

confidence: 99%

WITHDRAWN: Effect of Ruai-Sanyin formula maintenance therapy after completion of standard adjuvant treatment on survival in women with early-stage triple negative breast cancer: A multicenter prospective cohort study

Wang

Sun

Qin

et al. 2022

Preprint

View full text Add to dashboard Cite

Background Ruai-sanyin formula (RASYF) is composed of a variety of anticancer herbs. It is widely used in the treatment of triple negative breast cancer (TNBC) and has proved to inhibit tumor growth and lung metastasis in animal models, but there is no evidence for clinical application in the real world. Methods We conducted this prospective cohort study at 5 research centers in China from November 2016 to December 2018. RASYF was set as an exposure factor. TNBC patients within 3 months after completion of standard adjuvant treatment were included. The exposed group received RASYF treatment, while the non-exposed group received observation. The primary end point was disease-free survival (DFS). Secondary end points included, overall survival (OS), distant disease-free survival (DDFS), relapse-free survival (RFS), QLQ-BR23 assesses quality of life in patients and adverse events. Results A total of 613 eligible patients with operable TNBC were enrolled, of which 588 were included in the Full Protocol Set. At a median follow-up of 48 months, DFS time was longer in those assigned to RASYF compared with observation (3-year DFS, 89.6% vs. 83.5%, [HR = 0.61, 95%CI (0.39-0.95)]; P = 0.03). Similar outcomes were observed for RFS (3-year RFS, 92.1% vs. 85.9%, HR = 0.55, [95% CI, 0.34-0.91]; P = 0.02). However, there was no statistically significant difference in OS and DDFS between the groups. In exploratory subgroup analysis, RASYF benefits were greater in patients with age under the 40 (3-year DFS, 88.4% vs. 76.1%, [HR = 0.45, 95%CI (0.21-0.95)]; P = 0.03). And RASYF is helpful to the improvement of postoperative quality of life. Comparing to the observation group, RASYF increased the mean CFB of BR23 scores in body image (12.34 vs. 8.76, P = 0.03)，sexual function (11.79 vs. 9.23, P <0.01) , future perspective (9.90 vs. 6.53, P= 0.04), and decreased the scores of systemic therapy side effects (-12.41 vs. -9.24, P = 0.01). Safety analysis showed that RASYF caused major adverse reactions including impaired liver function (4.0%) and stomach pain (6.1%), but the overall security is controllable. Conclusion RASYF supplementation for 2 years after standard adjuvant chemoradiotherapy has certain clinical significance in preventing recurrence and metastasis and improving the quality of life of patients with early TNBC. Trial registration ClinicalTrials.gov: NCT03332368 Registered 6 November, 2017 (retrospectively registered)

show abstract

Section: Discussionmentioning

confidence: 99%

WITHDRAWN: Effect of Ruai-Sanyin formula maintenance therapy after completion of standard adjuvant treatment on survival in women with early-stage triple negative breast cancer: A multicenter prospective cohort study

Wang

Sun

Qin

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…Recruiting inflammatory cells to generate an inflammatory environment at the TME mediates EC cell metastasis. Thus, autophagy may be a promising marker and its inhibitors may be an approach to treat EC [11].…”

Section: Tumor Microenvironment (Tme)mentioning

confidence: 99%

Advances in esophageal cancer-specific tumor markers and immunotherapy

Guo

2024

Third International Conference on Biological Engineering and Medical Science (ICBioMed2023)

View full text Add to dashboard Cite

Esophageal cancer has a high fatality rate among common cancers. There are no obvious symptoms in the early stage of esophageal cancer, leading to untimely diagnosis and disease progression. Therefore, finding the right tumor markers to improve diagnostic accuracy and enable early detection and treatment is particularly important to reduce mortality and improve quality of life for patients. Traditional treatments are surgery, radiotherapy and chemotherapy, but the treatment effect is usually poor. Immunotherapy for oncology, represented by immune checkpoint inhibitors (ICIs), has been on the rise in recent years and is beginning to take its place in the first, second and third lines of treatment for esophageal cancer. In this review, some more studied tumor markers including DNA methylation, expression of miRNA and lncRNA, exosomes, tumor microenvironment and circulating tumor cells are summarized, and some promising immunotherapies, some are corresponding with markers, are introduced, providing a reference for the diagnosis and treatment of esophageal cancer.

show abstract

“…In recent decades, current studies noticed the significance of autophagy in the TME gradually, demonstrating that autophagy and immunity work synergistically to affect tumor progression, indicating that autophagy could become a potential target for cancer immunotherapy ( 23 , 24 ). Therefore, it is necessary to clarify the correlation between autophagy and various tumor-infiltrating immune cells in the TME and broaden new insights into cancer therapy.…”

Section: Autophagy and Tumor Immune Cell Infiltrationmentioning

confidence: 99%

Crosstalk between autophagy and immune cell infiltration in the tumor microenvironment

Yang

Zhang²,

Chen³

et al. 2023

Front. Med.

View full text Add to dashboard Cite

Autophagy is a conserved process for self-degradation and provides cells with a rescue mechanism to respond to circumstances such as stress and starvation. The role of autophagy in cancer is extremely complex and often paradoxical. Most of the related published studies on tumors are always focused on cancer cells. However, present studies gradually noticed the significance of autophagy in the tumor microenvironment. These studies demonstrate that autophagy and immunity work synergistically to affect tumor progression, indicating that autophagy could become a potential target for cancer immunotherapy. Therefore, it is crucial to clarify the correlation between autophagy and various tumor-infiltrating immune cells in the tumor microenvironment. The context-dependent role of autophagy is critical in the design of therapeutic strategies for cancer.

show abstract

The role of autophagy in initiation, progression, TME modification, diagnosis, and treatment of esophageal cancers

Cited by 8 publications

References 138 publications

WITHDRAWN: Effect of Ruai-Sanyin formula maintenance therapy after completion of standard adjuvant treatment on survival in women with early-stage triple negative breast cancer: A multicenter prospective cohort study

WITHDRAWN: Effect of Ruai-Sanyin formula maintenance therapy after completion of standard adjuvant treatment on survival in women with early-stage triple negative breast cancer: A multicenter prospective cohort study

Advances in esophageal cancer-specific tumor markers and immunotherapy

Crosstalk between autophagy and immune cell infiltration in the tumor microenvironment

Contact Info

Product

Resources

About